Novo Nordisk’s hemophilia treatment has received approval from the U.S. Food and Drug Administration (FDA). The FDA has approved Novo Nordisk’s Alhemo to reduce bleeding in hemophilia patients.
Hemophilia is a condition that impairs the body’s ability to form blood clots, leading to prolonged bleeding episodes. In the United States, approximately 33,000 individuals are affected by this disorder.
Current hemophilia treatments primarily involve replacement therapy, which administers clotting factors to normalize the blood clotting process. However, 30% of patients with hemophilia A and 5% to 15% of those with hemophilia B develop antibodies against these clotting factors, reducing the effectiveness of traditional replacement therapy.
Alhemo is approved for use in adolescents and adults aged 12 and older who have developed such antibodies. Administered via subcutaneous injection, Alhemo aims to enhance the effectiveness of replacement therapy and reduce bleeding.
Meanwhile, current hemophilia treatments include Pfizer’s injection HYMPAVZI, approved in October, and several gene therapies.
Most Commented